Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ALPINE 4 aldafermin in compensated cirrhosis due to NASH
2019-002341-38Phase 2Unknown
- Sponsor
- NGM Biopharmaceuticals
- Start
- Apr 2020
- Modality
- Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in metabolic dysfunction-associated steatohepatitis (MASH) and Cirrhosis comparing Aldafermin with Placebo (2 arms). Primary endpoint: Histologic response at Week 48. Status: unknown.
02
Drugs
aldafermin
03
Conditions
metabolic dysfunction-associated steatohepatitis (MASH)Cirrhosis
Beyond the preview
Go deeper on 2019-002341-38.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2019-002341-38.